适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- INSERM
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid ArthritisMedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859Rheumatoid ArthritisCTIS2023-505127-31-00IGM Biosciences Inc.24
进行中（未招募）
1 期
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune ThrombocytopeniaPrimary immune thrombocytopenia (ITP)MedDRA version: 23.0Level: PTClassification code: 10083842Term: Immune thrombocytopenia Class: 100000004851CTIS2023-508819-23-00Hutchmed Ltd.51
进行中（未招募）
不适用
/AEUCTR2011-000221-68-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
已完成
2 期
EuroSkinGraft - Novomaix phase II A phase 2, intra-patient randomised controlled multicentre international study to evaluate the efficacy of an acellular dermal template Novomaix for the treatment of full thickness skin defects.Full thickness skin defectsscar problems1001498210040795NL-OMON41095niversity of Zurich - Tissue Biology Research Unit15
招募中
1 期
A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritisCTIS2023-507393-40-00selectION Therapeutics GmbH40